TY - JOUR
T1 - SARS-CoV-2 variants impact RBD conformational dynamics and ACE2 accessibility
AU - Valério, Mariana
AU - Borges-Araújo, Luís
AU - Melo, Manuel N.
AU - Lousa, Diana
AU - Soares, Cláudio M.
N1 - Funding Information:
MV thanks FCT for the PhD fellowship SFRH/BD/148542/2019. LB-A thanks the Medical Biochemistry and Biophysics Doctoral Program (M2B-PhD) and Fundação para a Ciência e a Tecnologia, I.P. (FCT) for PhD fellowship PD/BD/137492/2018. MM thanks FCT for fellowship CEECIND/04124/2017. DL acknowledges FCT project PTDC/CCI-BIO/28200/2017. CS and MM further acknowledge the associated Laboratory LS4FUTURE and FCT project MOSTMICRO-ITQB, with references UIDB/04612/2020 and UIDP/04612/2020. Acknowledgments
Funding Information:
MV thanks FCT for the PhD fellowship SFRH/BD/148542/2019. LB-A thanks the Medical Biochemistry and Biophysics Doctoral Program (M2B-PhD) and Fundação para a Ciência e a Tecnologia, I.P. (FCT) for PhD fellowship PD/BD/137492/2018. MM thanks FCT for fellowship CEECIND/04124/2017. DL acknowledges FCT project PTDC/CCI-BIO/28200/2017. CS and MM further acknowledge the associated Laboratory LS4FUTURE and FCT project MOSTMICRO-ITQB, with references UIDB/04612/2020 and UIDP/04612/2020.
Publisher Copyright:
2022 Valério, Borges-Araújo, Melo, Lousa and Soares.
PY - 2022
Y1 - 2022
N2 - Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has killed over 6 million people and is having a devastating social and economic impact around the world. The rise of new variants of concern (VOCs) represents a difficult challenge due to the loss of vaccine and natural immunity, as well as increased transmissibility. All VOCs contain mutations in the spike glycoprotein, which mediates fusion between the viral and host cell membranes. The spike glycoprotein binds to angiotensin-converting enzyme 2 (ACE2) via its receptor binding domain (RBD) initiating the infection process. Attempting to understand the effect of RBD mutations in VOCs, a lot of attention has been given to the RBD-ACE2 interaction. However, this type of analysis ignores more indirect effects, such as the conformational dynamics of the RBD itself. Observing that some mutations occur in residues that are not in direct contact with ACE2, we hypothesized that they could affect the RBD conformational dynamics. To test this, we performed long atomistic (AA) molecular dynamics (MD) simulations to investigate the structural dynamics of wt RBD, and that of four VOCs (Alpha, Beta, Delta, and Omicron). Our results show that the wt RBD presents two distinct conformations: an “open” conformation where it is free to bind ACE2; and a “closed” conformation, where the RBM ridge blocks the binding surface. The Alpha and Beta variants shift the open/closed equilibrium towards the open conformation by roughly 20%, likely increasing ACE2 binding affinity. Simulations of the Delta and Omicron variants showed extreme results, with the closed conformation being rarely observed. The Delta variant also differed substantially from the other variants, alternating between the open conformation and an alternative “reversed” one, with a significantly changed orientation of the RBM ridge. This alternate conformation could provide a fitness advantage due to increased availability for ACE2 binding, and by aiding antibody escape through epitope occlusion. These results support the hypothesis that VOCs, and particularly the Omicron and Delta variants, impact RBD conformational dynamics in a direction that promotes efficient binding to ACE2 and, in the case of Delta, may assist antibody escape.
AB - Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has killed over 6 million people and is having a devastating social and economic impact around the world. The rise of new variants of concern (VOCs) represents a difficult challenge due to the loss of vaccine and natural immunity, as well as increased transmissibility. All VOCs contain mutations in the spike glycoprotein, which mediates fusion between the viral and host cell membranes. The spike glycoprotein binds to angiotensin-converting enzyme 2 (ACE2) via its receptor binding domain (RBD) initiating the infection process. Attempting to understand the effect of RBD mutations in VOCs, a lot of attention has been given to the RBD-ACE2 interaction. However, this type of analysis ignores more indirect effects, such as the conformational dynamics of the RBD itself. Observing that some mutations occur in residues that are not in direct contact with ACE2, we hypothesized that they could affect the RBD conformational dynamics. To test this, we performed long atomistic (AA) molecular dynamics (MD) simulations to investigate the structural dynamics of wt RBD, and that of four VOCs (Alpha, Beta, Delta, and Omicron). Our results show that the wt RBD presents two distinct conformations: an “open” conformation where it is free to bind ACE2; and a “closed” conformation, where the RBM ridge blocks the binding surface. The Alpha and Beta variants shift the open/closed equilibrium towards the open conformation by roughly 20%, likely increasing ACE2 binding affinity. Simulations of the Delta and Omicron variants showed extreme results, with the closed conformation being rarely observed. The Delta variant also differed substantially from the other variants, alternating between the open conformation and an alternative “reversed” one, with a significantly changed orientation of the RBM ridge. This alternate conformation could provide a fitness advantage due to increased availability for ACE2 binding, and by aiding antibody escape through epitope occlusion. These results support the hypothesis that VOCs, and particularly the Omicron and Delta variants, impact RBD conformational dynamics in a direction that promotes efficient binding to ACE2 and, in the case of Delta, may assist antibody escape.
KW - MD simulations
KW - receptor binding domain (RBD)
KW - ridge
KW - SARS-CoV-2
KW - variants of concern (VOCs)
UR - http://www.scopus.com/inward/record.url?scp=85146329813&partnerID=8YFLogxK
U2 - 10.3389/fmedt.2022.1009451
DO - 10.3389/fmedt.2022.1009451
M3 - Article
AN - SCOPUS:85146329813
SN - 2673-3129
VL - 4
JO - Frontiers in Medical Technology
JF - Frontiers in Medical Technology
M1 - 1009451
ER -